Patent · US Active

Antibody therapies for human immunodeficiency virus (HIV)

US11845788B2 · kind B2 · utility

0Cited by

9References

13Claims

0Family size

Assignee

Beth Israel Deaconess Medical Center, Inc. · US

Inventors

Dan H. Barouch · Newton, US
Bruce A. Kerwin · Bainbridge Island, US
Randal R. Ketchem · Snohomish, US
Alison J. Gillespie · San Diego, US
Christine C. Siska · Seattle, US
Rutilio Clark · Bainbridge Island, US
Julee A. Floyd · Seattle, US
Jeremy Martin Shaver · Lake Forest Park, US
Richard S. Rogers · Seattle, US

Key dates

Filing date	May 22, 2019
Grant date	Dec 19, 2023
Priority date	—
Expiry date	May 22, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/16043
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Featured are PGT121 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating subjects infected with HIV and/or blocking HIV infections in subjects at risk of HIV transmission using the PGT121 variant antibodies or fragments thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.